… RNA-based combination therapy in a physiologically relevant mouse model of human lung
cancer. The effective delivery of small RNAs to solid tumors in the model, combined with the …

… cancer. Focus is primarily on rationales for the selection of specific combination therapies for
lung cancer … dosage regimens for the combinations, tested in preclinical and clinical trials. …

… lung cancer have led to improvements in tackling such resistance. The potential role for PET
in the management of erlotinib therapy, novel combination therapies … in lung cancer therapy, …

… and cells, the combination of these drugs may achieve greater therapeutic effects in the …
of the combination therapy for immunotherapy of SCLC to find out the rational combination …

… %-40% in combination therapy, non-small cell lung cancer (NSCLC) … combination of
gemcitabine plus cisplatin are approximately 28%-54% in phase II trials. Recently, this combination …

… The goal of the study was to identify combination therapies for lung tumors harboring KRAS
mutations. An initial whole-genome shRNA screen performed to identify complementary …

… and rationally designed drug combination therapies. In this Review, we provide an overview
of the recent progress made in lung cancer biology and treatment, … Biology of lung cancer …

… the lung tumor growth and killed the lung cancer cells in vivo and in vitro. The synergistic
anti-tumor efficacy was assessed in NCL-H460 and NCL-H460 cell-treated mice lung cancer …

… therapies combined with chemotherapy, targeted therapy or … combination therapeutic
strategies in advanced NSCLC. … This article summarizes the combination therapy of existing …

… The P/T-LPNs combination effects on human lung cancer cells were studied. Therapeutic …
The P/T-LPNs combination effects on human lung cancer cells were investigated. Citation…